Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson & Johnson, has received US Food and Drug Administration (FDA) approval for Tracleer (bosentan) to be used in paediatric patients with idiopathic or congenital pulmonary arterial hypertension (PAH).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The FDA has granted approval for a new 32mg tablet for oral suspension for Tracleer to treat PAH patients aged three and older.

PAH is a chronic and progressive disease that results in abnormally high blood pressure in the arteries between the heart and lungs of an affected person.

The life-threatening disorder does not allow the blood to flow normally through the lungs and forces the patient’s heart to work harder.

Tracleer is an orally active endothelin receptor antagonist (ERA) that can be used to treat PAH patients by blocking the effects of the extra endothelin produced by their bodies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The therapy has the potential to improve pulmonary vascular resistance (PVR), which is expected to improve the patient’s exercising ability.

"Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001."

Actelion Pharmaceuticals US Medical senior vice-president Dr Gary Palmer said: “Actelion has focused on the needs of the PAH community since Tracleer, our first treatment for PAH, was approved in 2001.

“We’re pleased our portfolio of treatments continues to grow and paediatric PAH patients will now have an FDA-approved treatment option available.”

The Actelion medicine is currently the first treatment approved by the FDA for paediatric PAH patients in the US.

The company expects to make the 32mg oral treatment available by the fourth quarter of this year.

Image: Micrograph showing arteries in pulmonary hypertensive with marked thickening of the walls. Photo: courtesy of Yale Rosen from USA.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact